At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
RAD001 (everolimus)drug
Likely dose
RAD001 (everolimus) 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating RAD001 (everolimus) for Small Cell Lung Cancer. Completed, enrolled 40 participants across 19 sites.
Detailed Summary
This is a phase II, two-stage, open-label, single-agent study of the experimental drug RAD001 (everolimus) in patients with previously treated small cell lung cancer. RAD001 will be administered orally at a dose of 10 mg daily.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall Cell Lung Cancer
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2006
Enrollment StartOct 2006
Primary CompletionDec 2008
Study CompletionJun 2012
TodayJul 2026
First PostedSep 8, 2006
Enrollment StartOct 1, 2006
Primary CompletionDec 1, 2008
Study CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 19.8 years ago
Interventions
RAD001 (everolimus)drug
10 mg by mouth daily without interruption for 3-week cycles until disease progression or intolerable toxicities